What is CollPlant Biotechnologies Ltd's earnings per share (EPS)?

CollPlant Biotechnologies Ltd (CLGN) reported diluted earnings per share of -$0.94 for fiscal year 2025. This represents a 35.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CollPlant Biotechnologies Ltd (CLGN) Financials

CLGN

FY2025 annual

Revenue $2.4M +360.4% YoY

Net Income -$11.5M +30.8% YoY

EPS (Diluted) -$0.94 +35.2% YoY

Free Cash Flow -$9.4M +35.2% YoY

Market Cap $7.8M as of Oct 15, 2026

Price / Sales 3.3x on $2.4M revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.3x on $6.1M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Mar 26, 2026 Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Mar 26, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CLGN SEC filings page.

CollPlant Biotechnologies Ltd (CLGN) reported $2.4M in revenue for fiscal year 2025, up 360.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CLGN FY2025 2026-10-03

CollPlant operates as a development-stage biotech: revenue returned, but R&D still drives losses and external financing supports the balance sheet.

In FY2025, revenue recovered to $2.4M from $515K, yet R&D remained $8.2M, so the business is still investment-led rather than scale-led. The near match between a net loss of $11.5M and operating cash flow of -$9.4M means reported losses are translating into cash use, not arising mainly from noncash charges.

Development spending remains disproportionate to commercial revenue: R&D was $8.2M against FY2025 revenue of $2.4M, leaving product investment several times larger than reported sales. Revenue nevertheless improved from FY2024 while R&D declined, indicating better spending efficiency without yet reaching operating break-even.

The balance sheet is shrinking while financing needs rise: total assets fell to $10.8M from $18.7M in FY2024, while debt-to-equity reached 0.8x. FY2025 financing cash flow of $3.1M coincided with shares rising to 12.8M, and reported cash and investments equaled 7.1 months of the latest annual operating outflow.

Financial Health Signals

Financial Health Score 40/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of CollPlant Biotechnologies Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

CollPlant Biotechnologies Ltd held $5.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $9.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and CollPlant Biotechnologies Ltd scores 23/100 among other emerging companies.

Dilution

CollPlant Biotechnologies Ltd had 13M shares outstanding at the end of fiscal year 2025, against 11M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and CollPlant Biotechnologies Ltd scores 56/100 among other emerging companies.

R&D Intensity

CollPlant Biotechnologies Ltd spent $8.2M on research and development in fiscal year 2025, which was 59.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and CollPlant Biotechnologies Ltd scores 82/100 among other emerging companies.

Revenue Progress

CollPlant Biotechnologies Ltd reported revenue of $2.4M in fiscal year 2025, against $515K in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and CollPlant Biotechnologies Ltd scores 5/100 among other emerging companies.

Burn Trend

CollPlant Biotechnologies Ltd's operations used $9.4M of cash in fiscal year 2025, against $14.1M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and CollPlant Biotechnologies Ltd scores 10/100 among other emerging companies.

Balance Sheet

CollPlant Biotechnologies Ltd's cash, cash equivalents and investments came to $5.6M at the end of fiscal year 2025, against $4.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and CollPlant Biotechnologies Ltd scores 63/100 among other emerging companies.

Altman Z-Score Distress

-18.05

CollPlant Biotechnologies Ltd scores -18.05, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($7.8M) relative to total liabilities ($4.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

CollPlant Biotechnologies Ltd passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

CollPlant Biotechnologies Ltd reported a net loss of $11.5M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt

$5.6M

YoY-53.1%

QoQ-51.1%

CollPlant Biotechnologies Ltd held $5.6M in cash as of Q4 2025; long-term debt is not reported for that period.

Shares Outstanding

13M

YoY+11.8%

QoQ+0.7%

CollPlant Biotechnologies Ltd had 13M shares outstanding in Q4 2025. This represents an increase of 11.8% from the same quarter a year earlier. Against the prior quarter it is up 0.7%.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

CLGN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLGN quarterly income statement

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Revenue	$2.4M+360.4%	$515K-95.3%	$11.0M+3565.2%	$299K-98.1%	$15.6M+154.9%	$6.1M+164.8%	$2.3M-53.8%	$5.0M	N/A
Cost of Revenue	$835K-48.6%	$1.6M-18.4%	$2.0M+397.8%	$400K-80.0%	$2.0M-33.2%	$3.0M+59.8%	$1.9M+13.3%	$1.7M	N/A
Gross Profit	$1.5M+238.4%	-$1.1M-112.4%	$9.0M+8979.2%	-$101K-100.7%	$13.6M+335.0%	$3.1M+614.1%	$439K-86.9%	$3.4M	N/A
R&D Expenses	$8.2M-22.1%	$10.5M+0.3%	$10.5M+2.2%	$10.3M+34.4%	$7.6M+87.7%	$4.1M-7.9%	$4.4M+13.9%	$3.9M+563.9%	$584K
SG&A Expenses	$4.8M-14.1%	$5.6M-6.2%	$6.0M-11.1%	$6.7M+13.5%	$5.9M+27.2%	$4.7M+27.7%	$3.7M-1.8%	$3.7M	N/A
Operating Income	-$11.5M+33.4%	-$17.3M-129.6%	-$7.5M+56.1%	-$17.1M-26403.1%	$65K+101.2%	-$5.6M+26.6%	-$7.6M-79.8%	-$4.2M	N/A
EBITDA	-$10.6M+34.8%	-$16.2M-152.9%	-$6.4M+60.0%	-$16.0M-2011.8%	$838K+117.0%	-$4.9M+30.4%	-$7.1M-81.7%	-$3.9M	N/A
Income Tax	N/A	$46.0M-23.3%	$60.0M	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$11.5M+30.8%	-$16.6M-136.6%	-$7.0M+58.5%	-$16.9M-7241.4%	$237K+104.1%	-$5.8M+48.3%	-$11.2M-78.7%	-$6.2M	N/A
EPS (Basic)	-$0.94+35.2%	-$1.45-133.9%	-$0.62+59.5%	-$1.53-7750.0%	$0.02+102.4%	-$0.84+62.3%	-$2.23	N/A	N/A
EPS (Diluted)	-$0.94+35.2%	-$1.45-133.9%	-$0.62+59.5%	-$1.53-7750.0%	$0.02	-$0.84+62.3%	-$2.23	N/A	N/A
Diluted Shares (Avg)	12M+6.5%	11M+0.6%	11M+3.2%	11M-7.8%	12M	7M+38.1%	5M	N/A	N/A

Metric	Q4'2520-F	Q2'256-K	Q4'2420-F	Q2'246-K	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q
Revenue	N/A	$179K-28.1%	N/A	$249K-97.6%	N/A	$10.2M+15330.3%	N/A	$66K-90.4%
Cost of Revenue	N/A	$186K-65.3%	N/A	$536K-12.8%	N/A	$615K+1330.2%	N/A	$43K-90.0%
Gross Profit	N/A	-$7K+97.6%	N/A	-$287K-103.0%	N/A	$9.6M+41504.3%	N/A	$23K-91.2%
R&D Expenses	N/A	$2.0M-25.4%	N/A	$2.7M+4.8%	N/A	$2.6M-1.0%	N/A	$2.6M+36.7%
SG&A Expenses	N/A	$1.2M-18.6%	N/A	$1.4M+7.9%	N/A	$1.3M-18.1%	N/A	$1.6M+13.0%
Operating Income	N/A	-$3.2M+27.9%	N/A	-$4.4M-177.6%	N/A	$5.7M+235.7%	N/A	-$4.2M-36.6%
Net Income	N/A	-$3.3M+20.5%	N/A	-$4.2M-173.1%	N/A	$5.8M+234.5%	N/A	-$4.3M-41.0%
EPS (Basic)	N/A	$0.28-24.3%	N/A	$0.37-27.5%	N/A	$0.51+230.8%	N/A	-$0.39-30.0%
EPS (Diluted)	N/A	$0.28-24.3%	N/A	$0.37-24.5%	N/A	$0.49+225.6%	N/A	-$0.39-30.0%
Diluted Shares (Avg)	N/A	12M+3.4%	N/A	11M-2.7%	N/A	12M+6.2%	N/A	11M+8.7%

Not reported in any period shown, so not listed: EBITDA, Interest Expense, Income Tax.

CLGN Balance Sheet

CLGN quarterly balance sheet

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Total Assets	$10.8M-42.4%	$18.7M-45.2%	$34.1M-9.6%	$37.8M-26.3%	$51.2M+372.5%	$10.8M+0.8%	$10.8M	N/A	N/A
Current Assets	$6.7M-48.8%	$13.2M-53.0%	$28.0M-11.5%	$31.7M-29.8%	$45.1M+694.3%	$5.7M+12.6%	$5.0M	N/A	N/A
Cash & Equivalents	$5.6M-53.1%	$11.9M-55.4%	$26.7M-10.0%	$29.7M+125.5%	$13.1M+294.5%	$3.3M-12.1%	$3.8M-29.2%	$5.4M+1.3%	$5.3M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$573K+30.2%	$440K-38.4%	$714K-50.1%	$1.4M+32.3%	$1.1M-14.3%	$1.3M+42.1%	$888K	N/A	N/A
Accounts Receivable	$1K-99.3%	$150K	N/A	$9K-96.7%	$270K-67.5%	$830K+950.6%	$79K	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$4.7M-10.3%	$5.2M-9.4%	$5.8M+5.4%	$5.5M-10.1%	$6.1M-4.1%	$6.4M-4.5%	$6.7M	N/A	N/A
Current Liabilities	$2.7M-10.0%	$3.0M-8.6%	$3.3M+4.7%	$3.1M+3.0%	$3.0M-11.0%	$3.4M-2.0%	$3.5M	N/A	N/A
Non-Current Liabilities	$2.0M-10.7%	$2.3M-10.3%	$2.5M+6.4%	$2.4M-22.9%	$3.1M+3.8%	$3.0M-7.2%	$3.2M	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	$30K+172.7%	$11K-82.5%	$63K	N/A	$2.0M
Total Equity	$6.1M-54.8%	$13.5M-52.5%	$28.3M-12.2%	$32.3M-28.5%	$45.1M+907.8%	$4.5M+9.5%	$4.1M-24.6%	$5.4M+4.8%	$5.2M
Retained Earnings	-$124.8M-10.1%	-$113.3M-17.2%	-$96.7M-7.8%	-$89.7M-23.2%	-$72.8M+0.3%	-$73.0M-8.6%	-$67.3M	N/A	N/A

Metric	Q4'2520-F	Q2'256-K	Q4'2420-F	Q2'246-K	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q
Total Assets	$10.8M-42.4%	$17.4M-34.4%	$18.7M-45.2%	$26.6M-36.1%	$34.1M-9.6%	$41.6M-6.4%	$37.8M-26.3%	$44.4M-19.3%
Current Assets	$6.7M-48.8%	$12.6M-37.9%	$13.2M-53.0%	$20.3M-41.7%	$28.0M-11.5%	$34.9M-8.9%	$31.7M-29.8%	$38.3M-23.1%
Cash & Equivalents	$5.6M-53.1%	$11.4M-39.6%	$11.9M-55.4%	$18.9M-15.1%	$26.7M-10.0%	$22.3M-38.6%	$29.7M+125.5%	$36.3M+107.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$573K+30.2%	$553K+26.0%	$440K-38.4%	$439K-71.7%	$714K-50.1%	$1.6M+14.5%	$1.4M+32.3%	$1.4M+44.3%
Accounts Receivable	$1K-99.3%	N/A	$150K	$250K	N/A	N/A	$9K-96.7%	$9K-96.8%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$4.7M-10.3%	$4.9M-15.5%	$5.2M-9.4%	$5.8M+5.6%	$5.8M+5.4%	$5.5M+12.7%	$5.5M-10.1%	$4.9M-12.1%
Current Liabilities	$2.7M-10.0%	$2.7M-15.4%	$3.0M-8.6%	$3.2M+16.5%	$3.3M+4.7%	$2.8M+17.8%	$3.1M+3.0%	$2.4M-19.5%
Non-Current Liabilities	$2.0M-10.7%	$2.2M-15.6%	$2.3M-10.3%	$2.6M-5.5%	$2.5M+6.4%	$2.7M+7.9%	$2.4M-22.9%	$2.5M-3.9%
Total Equity	$6.1M-54.8%	$12.5M-39.7%	$13.5M-52.5%	$20.7M-42.5%	$28.3M-12.2%	$36.0M-8.8%	$32.3M-28.5%	$39.5M-20.1%
Retained Earnings	-$124.8M-10.1%	-$118.1M-12.4%	-$113.3M-17.2%	-$105.1M-19.9%	-$96.7M-7.8%	-$87.7M-8.3%	-$89.7M-23.2%	-$80.9M-22.7%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

CLGN Cash Flow Statement

CLGN quarterly cash flow statement

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Operating Cash Flow	-$9.4M+33.2%	-$14.1M-410.1%	-$2.8M+79.8%	-$13.7M-647.7%	$2.5M+156.2%	-$4.5M+22.0%	-$5.7M-368.6%	-$1.2M	N/A
Depreciation & Amortization	$912K-12.1%	$1.0M-5.8%	$1.1M+2.4%	$1.1M+39.2%	$773K+17.1%	$660K+22.4%	$539K+57.6%	$342K	N/A
Stock-Based Compensation	$999K-41.9%	$1.7M-11.3%	$1.9M-10.9%	$2.2M+36.1%	$1.6M-4.6%	$1.7M+48.8%	$1.1M-21.5%	$1.4M	N/A
Capital Expenditures	$28K-94.2%	$483K-49.4%	$954K-25.1%	$1.3M-10.8%	$1.4M+226.8%	$437K-70.7%	$1.5M+79.2%	$832K	N/A
Free Cash Flow	-$9.4M+35.2%	-$14.6M-292.1%	-$3.7M+75.2%	-$15.0M-1495.3%	$1.1M+122.0%	-$4.9M+32.1%	-$7.2M-251.1%	-$2.0M	N/A
Investing Cash Flow	-$27K+95.0%	-$539K+53.4%	-$1.2M-104.0%	$28.9M+191.7%	-$31.6M-5980.2%	-$519K+64.5%	-$1.5M-75.6%	-$832K	N/A
Financing Cash Flow	$3.1M+34366.7%	$9K-99.2%	$1.1M-40.9%	$1.9M-95.2%	$38.8M+768.1%	$4.5M-17.5%	$5.4M+96.5%	$2.8M	N/A

Metric	Q4'2520-F	Q2'256-K	Q4'2420-F	Q2'246-K	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q
Stock-Based Compensation	N/A	$356K-27.3%	N/A	$490K+45.0%	N/A	$338K	N/A	N/A

Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

CLGN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLGN quarterly financial ratios

Metric	FY2520-F	FY2420-F	FY2320-F	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Gross Margin	64.8%	-215.5%	81.8%+115.6pp	-33.8%-121.0pp	87.2%+36.1pp	51.1%+32.1pp	18.9%-48.0pp	66.9%	N/A
Operating Margin	-484.3%	-3349.7%	-68.5%	-5718.1%	0.4%+91.6pp	-91.2%	-329.2%	-84.7%	N/A
Net Margin	-484.6%	-3225.1%	-64.0%	-5660.5%	1.5%+95.6pp	-94.1%	-481.6%	-124.6%	N/A
Return on Equity	-188.9%-65.6pp	-123.4%-98.6pp	-24.8%+27.7pp	-52.4%-53.0pp	0.5%+129.5pp	-129.0%+144.1pp	-273.1%-157.8pp	-115.3%	N/A
Return on Assets	-106.5%-17.8pp	-88.8%-68.2pp	-20.6%+24.2pp	-44.8%-45.3pp	0.5%+53.7pp	-53.3%+50.6pp	-103.8%	N/A	N/A
Current Ratio	2.53-1.9x	4.44-4.2x	8.62-1.6x	10.20-4.8x	14.96+13.3x	1.68+0.2x	1.46	N/A	N/A
Debt-to-Equity	0.77+0.4x	0.39+0.2x	0.200.0x	0.17+0.2x	0.000.0x	0.000.0x	0.02	N/A	0.39
Asset Turnover	0.22+0.2x	0.03-0.3x	0.32+0.3x	0.01-0.3x	0.31-0.3x	0.57+0.4x	0.22	N/A	N/A
FCF Margin	-398.4%	-2830.3%	-33.9%	-5007.4%	6.9%+86.5pp	-79.7%	-310.3%	-40.9%	N/A

Metric	Q4'2520-F	Q2'256-K	Q4'2420-F	Q2'246-K	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q
Gross Margin	N/A	-3.9%	N/A	-115.3%	N/A	94.0%+59.1pp	N/A	34.8%-3.1pp
Operating Margin	N/A	-1775.4%	N/A	-1769.5%	N/A	55.7%	N/A	-6340.9%
Net Margin	N/A	-1869.8%	N/A	-1690.8%	N/A	56.6%	N/A	-6492.4%
Return on Equity	N/A	-26.8%-6.5pp	N/A	-20.3%-36.3pp	N/A	16.0%+26.8pp	N/A	-10.8%-4.7pp
Return on Assets	N/A	-19.2%-3.3pp	N/A	-15.8%-29.7pp	N/A	13.9%+23.5pp	N/A	-9.7%-4.1pp
Current Ratio	2.53-1.9x	4.60-1.7x	4.44-4.2x	6.27-6.3x	8.62-1.6x	12.53-3.7x	10.20-4.8x	16.21-0.8x
Debt-to-Equity	0.77+0.4x	0.39+0.1x	0.39+0.2x	0.28+0.1x	0.200.0x	0.150.0x	0.17+0.2x	0.120.0x
Asset Turnover	N/A	0.010.0x	N/A	0.01-0.2x	N/A	0.24+0.2x	N/A	0.000.0x

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
CollPlant Biotechnologies Ltd CLGN	FY2025	$2.4M	-$11.5M	N/A	$7.8M	40/100
Senti Biosciences Holdings, Inc. SNTI	FY2025	$22K	-$61.4M	N/A	$7.9M	—
CASI Pharmaceuticals, Inc. CASI	FY2025	$20.7M	-$48.1M	N/A	$4.3M	21/100
Dyadic International, Inc. DYAI	FY2025	$3.1M	-$7.4M	N/A	$16.9M	49/100
Mersana Therapeutics, Inc. MRSN	FY2024	$40.5M	-$69.2M	N/A	$145.4M	54/100
LakeShore Biopharma Co., Ltd LSB	FY2025	$85.7M	-$13.9M	-16.3%	$25.8M	48/100

Where CollPlant Biotechnologies Ltd Ranks

Frequently Asked Questions

What is CollPlant Biotechnologies Ltd's annual revenue?

CollPlant Biotechnologies Ltd (CLGN) reported $2.4M in total revenue for fiscal year 2025. This represents a 360.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is CollPlant Biotechnologies Ltd's revenue growing?

CollPlant Biotechnologies Ltd (CLGN) revenue grew by 360.4% year-over-year, from $515K to $2.4M in fiscal year 2025.

Is CollPlant Biotechnologies Ltd profitable?

No, CollPlant Biotechnologies Ltd (CLGN) reported a net income of -$11.5M in fiscal year 2025.

What is CollPlant Biotechnologies Ltd's EBITDA?

CollPlant Biotechnologies Ltd (CLGN) had EBITDA of -$10.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is CollPlant Biotechnologies Ltd's gross margin?

CollPlant Biotechnologies Ltd (CLGN) had a gross margin of 64.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is CollPlant Biotechnologies Ltd's return on equity (ROE)?

CollPlant Biotechnologies Ltd (CLGN) has a return on equity of -188.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is CollPlant Biotechnologies Ltd's free cash flow?

CollPlant Biotechnologies Ltd (CLGN) recorded an outflow of $9.4M in free cash flow during fiscal year 2025. This represents a 35.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is CollPlant Biotechnologies Ltd's operating cash flow?

CollPlant Biotechnologies Ltd (CLGN) recorded an outflow of $9.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are CollPlant Biotechnologies Ltd's total assets?

CollPlant Biotechnologies Ltd (CLGN) had $10.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are CollPlant Biotechnologies Ltd's capital expenditures?

CollPlant Biotechnologies Ltd (CLGN) invested $28K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does CollPlant Biotechnologies Ltd spend on research and development?

CollPlant Biotechnologies Ltd (CLGN) invested $8.2M in research and development during fiscal year 2025.

How many shares does CollPlant Biotechnologies Ltd have outstanding?

CollPlant Biotechnologies Ltd (CLGN) had 13M shares outstanding as of fiscal year 2025.

What is CollPlant Biotechnologies Ltd's current ratio?

CollPlant Biotechnologies Ltd (CLGN) had a current ratio of 2.53 as of fiscal year 2025, which is generally considered healthy.

What is CollPlant Biotechnologies Ltd's debt-to-equity ratio?

CollPlant Biotechnologies Ltd (CLGN) had a debt-to-equity ratio of 0.77 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is CollPlant Biotechnologies Ltd's return on assets (ROA)?

CollPlant Biotechnologies Ltd (CLGN) had a return on assets of -106.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is CollPlant Biotechnologies Ltd's P/E ratio?

CollPlant Biotechnologies Ltd (CLGN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $7.8M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is CollPlant Biotechnologies Ltd's price-to-sales ratio?

CollPlant Biotechnologies Ltd (CLGN) trades at 3.3x sales, its market capitalization divided by revenue of $2.4M revenue, FY2025. The market capitalization is $7.8M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does CollPlant Biotechnologies Ltd's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, CollPlant Biotechnologies Ltd (CLGN) held $5.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.4M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is CollPlant Biotechnologies Ltd's Altman Z-Score?

CollPlant Biotechnologies Ltd (CLGN) has an Altman Z-Score of -18.05, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is CollPlant Biotechnologies Ltd's Piotroski F-Score?

CollPlant Biotechnologies Ltd (CLGN) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are CollPlant Biotechnologies Ltd's earnings high quality?

CollPlant Biotechnologies Ltd (CLGN) reported a net loss of $11.5M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is CollPlant Biotechnologies Ltd?

CollPlant Biotechnologies Ltd (CLGN) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.